[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334820-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334820-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","frequency-of-androgen-receptor-positivity-in-tumors-a-study-evaluating-more-than-18000-tumors-article","Frequency of Androgen Receptor Positivity in Tumors: A Study Evaluating More Than 18,000 Tumors - Article","","Androgen receptor (AR) is a transcription factor and a therapeutic target in prostate cancer and potentially other malignancies. Using a tissue microarray with 18,234 samples spanning 141 tumor types and 608 samples from 76 normal tissue types, immunohistochemistry assessed AR positivity across tumors. Strong or moderate AR positivity showed tumor-entity specific patterns, while low AR staining correlated with more advanced stage, higher grade, nodal metastasis, and worse survival in several cancers.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/frequency-of-androgen-receptor-positivity-in-tumors-a-study-evaluating-more-than-18000-tumors-article/334820/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/frequency-of-androgen-receptor-positivity-in-tumors-a-study-evaluating-more-than-18000-tumors-article/334820.png","ImageObject",300,407,{"name":42,"@type":43},"Eliana","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the study design and sample scope?","Question",{"text":63,"@type":64},"A tissue microarray was analyzed by immunohistochemistry, containing 18,234 samples from 141 tumor types/subtypes and 608 samples from 76 normal tissue types.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which tumor types showed high AR positivity?",{"text":68,"@type":64},"High AR positivity (including strong positive cases) was detected in testicular sex cord-stromal tumors and prostate neoplasms, with additional entity-specific ranges reported across other cancer types.",{"name":70,"@type":61,"acceptedAnswer":71},"How was AR positivity related to prognosis and clinicopathological features?",{"text":72,"@type":64},"The study found associations between low AR staining and worse clinicopathological outcomes and reduced survival in specific cancers, while AR staining was reported as unrelated to features in some endometrial and ovarian carcinomas.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334820,1790519408,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":109,"preview_page_count":4},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","biomedicines  \nArticle  \nFrequency of Androgen Receptor Positivity in Tumors: A Study Evaluating More Than 18,000 Tumors  \nFlorian Viehweger 1, Jennifer Hoop 1, Lisa-Marie Tinger 1, Christian Bernreuther 1, Franziska Büscheck 1, Till S. Clauditz 1, Andrea Hinsch 1, Frank Jacobsen 1,2, Andreas M. Luebke 1, Stefan Steurer 1,  \nClaudia Hube-Magg 1, Martina Kluth 1, Andreas H. Marx 3, Till Krech 1,4, Patrick Lebok 1,4, Christoph Fraune 1,4, Eike Burandt 1, Guido Sauter 1, Ronald Simon 1, * and Sarah Minner 1  \nCitation: Viehweger, F.; Hoop, J.; Tinger, L.-M.; Bernreuther, C.; Büscheck, F.; Clauditz, T.S.; Hinsch, A.; Jacobsen, F.; Luebke, A.M.; Steurer, S.; et al. Frequency of Androgen Receptor Positivity in Tumors:  \nA Study Evaluating More Than 18,000 Tumors. Biomedicines 2024, 12, 957 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)biomedicines12050957  \nAcademic Editor: Akira Hara  \nReceived: 27 February 2024  \nRevised: 19 April 2024  \nAccepted: 22 April 2024  \nPublished: 25 April 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany; [f.viehweger@uke.de](f.viehweger@uke.de) (F.V.); [j.hoop@gmx.net](j.hoop@gmx.net) (J.H.); [c.bernreuther@uke.de](c.bernreuther@uke.de) (C.B.); [f.buescheck@uke.de](f.buescheck@uke.de) (F.B.); [t.clauditz@uke.de](t.clauditz@uke.de) (T.S.C.); [a.hinsch@uke.de](a.hinsch@uke.de) (A.H.); [f.jacobsen@uke.de](f.jacobsen@uke.de) (F.J.); [luebke@uke.de](luebke@uke.de) (A.M.L.); [s.steuer@uke.de](s.steuer@uke.de) (S.S.); [c.hube@uke.de](c.hube@uke.de) (C.H.-M.); [m.kluth@uke.de](m.kluth@uke.de) (M.K.); [t.krech@uke.de](t.krech@uke.de) (T.K.); [p.lebok@uke.de](p.lebok@uke.de) (P.L.); [c.fraune@uke.de](c.fraune@uke.de) (C.F.); [e.burandt@uke.de](e.burandt@uke.de) (E.B.); [g.sauter@uke.de](g.sauter@uke.de) (G.S.); [s.minner@uke.de](s.minner@uke.de) (S.M.)  \n2 Pathologie-Hamburg, Labor Lademannbogen Medizinisches Versorgungszentrum (MVZ) GmbH,  \n22339 Hamburg, Germany  \n3 Department of Pathology, Academic Hospital Fuerth, 90766 Fuerth, Germany; [andreas.marx@klinikum-fuerth.de](andreas.marx@klinikum-fuerth.de)  \n4 Institute of Pathology, Clinical Center Osnabrueck, 49076 Osnabrueck, Germany  \n* Correspondence: [r.simon@uke.de](r.simon@uke.de); Tel.: +49-40-7410-57214; Fax: +49-40-7410-55997  \nAbstract: Androgen receptor (AR) is a transcription factor expressed in various normal tissues and is a therapeutic target for prostate and possibly other cancers. A TMA containing 18,234 samples from 141 different tumor types/subtypes and 608 samples of 76 different normal tissue types was analyzed by immunohistochemistry. AR positivity was found in 116 tumor types including 66 tumor types (46.8%) with ≥1 strongly positive tumor. Moderate/strong AR positivity was detected in testicular sex cord-stromal tumors (93.3–100%) and neoplasms of the prostate (79.3–98.7%), breast (25.0–75.5%), other gynecological tumors (0.9–100%), kidney (5.0–44.1%), and urinary bladder (5.4–24.2%) . Low AR staining was associated with advanced tumor stage (pTa versus pT2-4; p \u003C 0.0001) in urothelial carcinoma; advanced pT (p \u003C 0.0001), high tumor grade (p \u003C 0.0001), nodal metastasis (p \u003C 0.0001), and reduced survival (p = 0.0024) in invasive breast carcinoma; high pT (p \u003C 0.0001) and grade (p \u003C 0.0001) in clear cell renal cell carcinoma (RCC); and high pT (p = 0.0055) as well as high grade (p \u003C 0.05) in papillary RCC. AR staining was unrelated to histopathological/clinical features in 157 endometrial carcinomas and in 221 ovarian carcinomas. Our data suggest a limited role of AR immunohistochemistry for tumor d","cbCaitXL4RgeJ63s","https://ap.wps.com/l/cbCaitXL4RgeJ63s","pdf",1803768,16,"English","# Introduction\n## Androgen receptor biology and expression\n## Variability of AR immunostaining across tumor types\n# Abstract","[{\"question\":\"What was the study design and sample scope?\",\"answer\":\"A tissue microarray was analyzed by immunohistochemistry, containing 18,234 samples from 141 tumor types/subtypes and 608 samples from 76 normal tissue types.\"},{\"question\":\"Which tumor types showed high AR positivity?\",\"answer\":\"High AR positivity (including strong positive cases) was detected in testicular sex cord-stromal tumors and prostate neoplasms, with additional entity-specific ranges reported across other cancer types.\"},{\"question\":\"How was AR positivity related to prognosis and clinicopathological features?\",\"answer\":\"The study found associations between low AR staining and worse clinicopathological outcomes and reduced survival in specific cancers, while AR staining was reported as unrelated to features in some endometrial and ovarian carcinomas.\"}]","Frequency of Androgen Receptor Positivity in Tumors: A Study Evaluating More Than 18,000 Tumors - Article | PDF",1790008442]